Gilead Keeps on Building
In the following video, Motley Fool health-care analyst David Williamson discusses a new E.U. approval for Gilead for its quad pill HIV drug cocktail, which has shares up 2% to near all-time highs. David tells investors why this is just one more piece to the puzzle for Gilead, as it continues to build its empire in the treatment of HIV.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Gilead Keeps on Building originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.